Amogh P. Belagodu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amogh P. Belagodu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Roberto Galvez
Carle Illinois College of Medicine, University of Illinois Urbana-Champaign
3 shared publications Angela G. Karountzos
Department of Psychology, University of Illinois at Urbana-Champaign, Champaign, IL, USA
1 shared publication- Bernard J. Slater
Center for Neural Circuits and Behavior and Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, USA
1 shared publication - Brent W. Roberts
Hector Research Institute of Education Sciences and Psychology, University of Tübingen, Tübingen, Germany
1 shared publication - Joshua M. Gulley
Department of Psychology, University of Illinois at Urbana-Champaign, USA; Neuroscience Program, University of Illinois at Urbana-Champaign, USA; Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, USA
1 shared publication - Lindsey R. Hammerslag
Institute for Biomedical Informatics, University of Kentucky, 760 Press Ave, Lexington, KY, 40508, United States of America
1 shared publication
Latest Publications
- 5 December 2017
- Published by Wiley in Addiction Biology
- Vol. 24 (2) , 193-205
Adolescent impulsivity as a sex‐dependent and subtype‐dependent predictor of impulsivity, alcohol drinking and dopamineD2receptor expression in adult rats
Impulsivity is a personality trait associated with a heightened risk for drug use and other psychiatric conditions. Because impulsivity‐related disorders typically emerge during adolescence, there has been interest in exploring methods for identifying adolescents that will be at risk to develop substance use disorders in adulthood. Here, we used a rodent model to assess inhibitory control (impulsive action) and impulsive decision making (impulsive choice) during adolescence (43–50 days old) or adulthood (93–100 days old) and then examined the impact of development on these impulsivity traits by re‐testing rats 50 days later. Impulsive action was not stable from adolescence to adulthood in male rats and was lowest in adult male rats, relative to adolescents and female rats. Impulsive choice was stable across development and unaffected by age or sex. Next, we examined the connection between our model of impulsivity and two measures relevant to substance abuse research: the initiation of voluntary alcohol drinking and dopamine D2receptor (D2R) expression in the prelimbic prefrontal cortex. Consumption of saccharin‐sweetened ethanol during 30‐minute sessions in adulthood was associated with adolescent, but not adult, impulsive action, particularly in male rats. Prelimbic D2R expression was reduced in individuals with high levels of impulsive choice, and this relationship appeared to be strongest among female rats. The results of this study demonstrate that impulsive choice, along with its connection to D2R expression, is relatively unchanged by the process of development. For impulsive action, however, individual levels of impulsivity during adolescence predict drinking in adulthood despite changes in the measure during development.
- 5 December 2017
- Published by Wiley in Addiction Biology
- Vol. 24 (2) , 193-205
Adolescent impulsivity as a sex‐dependent and subtype‐dependent predictor of impulsivity, alcohol drinking and dopamineD2receptor expression in adult rats
Impulsivity is a personality trait associated with a heightened risk for drug use and other psychiatric conditions. Because impulsivity‐related disorders typically emerge during adolescence, there has been interest in exploring methods for identifying adolescents that will be at risk to develop substance use disorders in adulthood. Here, we used a rodent model to assess inhibitory control (impulsive action) and impulsive decision making (impulsive choice) during adolescence (43–50 days old) or adulthood (93–100 days old) and then examined the impact of development on these impulsivity traits by re‐testing rats 50 days later. Impulsive action was not stable from adolescence to adulthood in male rats and was lowest in adult male rats, relative to adolescents and female rats. Impulsive choice was stable across development and unaffected by age or sex. Next, we examined the connection between our model of impulsivity and two measures relevant to substance abuse research: the initiation of voluntary alcohol drinking and dopamine D2receptor (D2R) expression in the prelimbic prefrontal cortex. Consumption of saccharin‐sweetened ethanol during 30‐minute sessions in adulthood was associated with adolescent, but not adult, impulsive action, particularly in male rats. Prelimbic D2R expression was reduced in individuals with high levels of impulsive choice, and this relationship appeared to be strongest among female rats. The results of this study demonstrate that impulsive choice, along with its connection to D2R expression, is relatively unchanged by the process of development. For impulsive action, however, individual levels of impulsivity during adolescence predict drinking in adulthood despite changes in the measure during development.
- 27 July 2017
- Published by Wiley in Developmental Neurobiology
- Vol. 77 (11) , 1321-1333
Neocortical developmental analysis of vasculature and their growth factors offer new insight into fragile X syndrome abnormalities
Fragile X Syndrome (FXS) is the most common single gene cause for Autism Spectrum Disorder and the most prevalent form of inherited mental retardation. Our prior studies have demonstrated that adult FXS mice have abnormal blood vessel density (BVD) and elevated Vascular Endothelial Growth Factor A expression (VEGF‐A). VEGF‐A is one of the most prominent regulators of BVD, and its abnormal expression is the most likely cause for FXS BVD abnormalities. We have demonstrated that attenuating elevated VEGF‐A expression can ameliorate many non‐vascular FXS abnormalities (Belagodu, Zendeli Slater and Galvez: Dev Neurobiol 77 (2017) 14–25), suggesting that abnormal VEGF‐A expression is an underlying cause for some FXS abnormalities. However, FXS is a developmental disorder and VEGF‐A's potential role in mediating FXS abnormalities during development have never been explored. Furthermore, VEGF‐A is one protein in a family of proteins (VEGF‐A, VEGF‐B, VEGF‐C, VEGF‐D, & PLGF) that activate one of three primary receptors (VEGFR1, VEGFR2, & VEGFR3). Abnormal expression of any of these proteins could hinder proper development. The current study demonstrated that FXS mice do not exhibit normal BVD developmental patterns, resulting in elevated adult expression, most likely due to observed elevated VEGF‐A adult expression. Interestingly, all five VEGF family of proteins exhibited altered developmental expression patterns that could cause abnormal development. However, none of the receptors exhibited abnormal adult expression, but did exhibit altered developmental expression. Expanding upon our prior analyses, the current study provides additional interesting insight towards potential developmental mechanisms mediating FXS abnormalities, while offering further sites for age specific therapeutic interventions. © 2017 Wiley Periodicals, Inc. Develop Neurobiol 77: 1321–1333, 2017
- 27 July 2017
- Published by Wiley in Developmental Neurobiology
- Vol. 77 (11) , 1321-1333
Neocortical developmental analysis of vasculature and their growth factors offer new insight into fragile X syndrome abnormalities
Fragile X Syndrome (FXS) is the most common single gene cause for Autism Spectrum Disorder and the most prevalent form of inherited mental retardation. Our prior studies have demonstrated that adult FXS mice have abnormal blood vessel density (BVD) and elevated Vascular Endothelial Growth Factor A expression (VEGF‐A). VEGF‐A is one of the most prominent regulators of BVD, and its abnormal expression is the most likely cause for FXS BVD abnormalities. We have demonstrated that attenuating elevated VEGF‐A expression can ameliorate many non‐vascular FXS abnormalities (Belagodu, Zendeli Slater and Galvez: Dev Neurobiol 77 (2017) 14–25), suggesting that abnormal VEGF‐A expression is an underlying cause for some FXS abnormalities. However, FXS is a developmental disorder and VEGF‐A's potential role in mediating FXS abnormalities during development have never been explored. Furthermore, VEGF‐A is one protein in a family of proteins (VEGF‐A, VEGF‐B, VEGF‐C, VEGF‐D, & PLGF) that activate one of three primary receptors (VEGFR1, VEGFR2, & VEGFR3). Abnormal expression of any of these proteins could hinder proper development. The current study demonstrated that FXS mice do not exhibit normal BVD developmental patterns, resulting in elevated adult expression, most likely due to observed elevated VEGF‐A adult expression. Interestingly, all five VEGF family of proteins exhibited altered developmental expression patterns that could cause abnormal development. However, none of the receptors exhibited abnormal adult expression, but did exhibit altered developmental expression. Expanding upon our prior analyses, the current study provides additional interesting insight towards potential developmental mechanisms mediating FXS abnormalities, while offering further sites for age specific therapeutic interventions. © 2017 Wiley Periodicals, Inc. Develop Neurobiol 77: 1321–1333, 2017
- 6 June 2016
- Published by Wiley in Developmental Neurobiology
- Vol. 77 (1) , 14-25
Blocking elevated VEGF‐A attenuates non‐vasculature Fragile X syndrome abnormalities
Fragile X syndrome (FXS) is the most common form of inherited mental retardation. In exploring abnormalities associated with the syndrome, we have recently demonstrated abnormal vascular density in a FXS mouse model (Galvan and Galvez, ). One of the most prominent regulators of vascular growth is VEGF‐A (Vascular Endothelial Growth Factor A), suggesting that FXS is associated with abnormal VEGF‐A expression. In addition to its role in vascular regulation, VEGF‐A also induces cellular changes such as increasing cell proliferation, and axonal and neurite outgrowth independent of its effects on vasculature. These VEGF‐A induced cellular changes are consistent with FXS abnormalities such as increased axonal material, dendritic spine density, and cell proliferation. In support of these findings, the following study demonstrated that FXS mice exhibit increased expression of VEGF‐A in brain. These studies suggest that increased VEGF‐A expression in FXS is contributing to non‐vascular FXS abnormalities. To explore the role of VEGF‐A in mediating non‐vascular FXS abnormalities, the monoclonal antibody Bevacizumab was used to block free VEGF‐A. Bevacizumab treatment was found to decrease FXS Synapsin‐1 expression, a presynaptic marker for synapse density, and reduce FXS testicle weight to control levels. Blocking VEGF‐A also alleviated FXS abnormalities on novel object recognition, a test of cognitive performance. These findings demonstrate that VEGF‐A is elevated in FXS brain and suggest that its expression promotes non‐vascular FXS abnormalities. © 2016 Wiley Periodicals, Inc. Develop Neurobiol 77: 14–25, 2017
- 6 June 2016
- Published by Wiley in Developmental Neurobiology
- Vol. 77 (1) , 14-25
Blocking elevated VEGF‐A attenuates non‐vasculature Fragile X syndrome abnormalities
Fragile X syndrome (FXS) is the most common form of inherited mental retardation. In exploring abnormalities associated with the syndrome, we have recently demonstrated abnormal vascular density in a FXS mouse model (Galvan and Galvez, ). One of the most prominent regulators of vascular growth is VEGF‐A (Vascular Endothelial Growth Factor A), suggesting that FXS is associated with abnormal VEGF‐A expression. In addition to its role in vascular regulation, VEGF‐A also induces cellular changes such as increasing cell proliferation, and axonal and neurite outgrowth independent of its effects on vasculature. These VEGF‐A induced cellular changes are consistent with FXS abnormalities such as increased axonal material, dendritic spine density, and cell proliferation. In support of these findings, the following study demonstrated that FXS mice exhibit increased expression of VEGF‐A in brain. These studies suggest that increased VEGF‐A expression in FXS is contributing to non‐vascular FXS abnormalities. To explore the role of VEGF‐A in mediating non‐vascular FXS abnormalities, the monoclonal antibody Bevacizumab was used to block free VEGF‐A. Bevacizumab treatment was found to decrease FXS Synapsin‐1 expression, a presynaptic marker for synapse density, and reduce FXS testicle weight to control levels. Blocking VEGF‐A also alleviated FXS abnormalities on novel object recognition, a test of cognitive performance. These findings demonstrate that VEGF‐A is elevated in FXS brain and suggest that its expression promotes non‐vascular FXS abnormalities. © 2016 Wiley Periodicals, Inc. Develop Neurobiol 77: 14–25, 2017